Subtype
Fallopian Tube Malignant Mixed Mesodermal (Mullerian) Tumor
CI-CAN-00002675Explore in graph →
6 active trials
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002675Explore in graph →
Clinical trials
13 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (4)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05494580 | Pamiparib Plus Surufatinib in Patients With Platinum-resistant Ovarian Cancer | completed | Phase 1 / Phase 2 | 29 | Sun Yat-sen UniversityOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT02020707 | Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers | completed | Phase 1 | 43 | Mayo ClinicOTHER | 1 | Jul 26, 2024 | clinicaltrials |
| NCT00989651 |
| Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer |
| completed |
| Phase 1 |
| 431 |
| National Cancer Institute (NCI)NIH |
| 1 |
| Oct 20, 2021 |
| clinicaltrials |
Data updated 22 days agoSource updated Mar 10, 2026source: clinicaltrials